Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Animal Sciences (1)
- Biochemical and Biomolecular Engineering (1)
- Biological Factors (1)
- Biomaterials (1)
-
- Biomedical Engineering and Bioengineering (1)
- Hematology (1)
- Life Sciences (1)
- Materials Science and Engineering (1)
- Medical Specialties (1)
- Molecular, Cellular, and Tissue Engineering (1)
- Nanoscience and Nanotechnology (1)
- Other Animal Sciences (1)
- Other Chemicals and Drugs (1)
- Other Pharmacy and Pharmaceutical Sciences (1)
- Pharmaceutical Preparations (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Polymer Science (1)
- Transport Phenomena (1)
Articles 1 - 2 of 2
Full-Text Articles in Chemicals and Drugs
Low Molecular Weight Glucosamine/L-Lactide Copolymers As Potential Carriers For The Development Of A Sustained Rifampicin Release System: Mycobacterium Smegmatis As A Tuberculosis Model, Jorge Ragusa
Department of Chemical and Biomolecular Engineering: Theses and Student Research
Tuberculosis, a highly contagious disease, ranks as the second leading cause of death from an infectious disease, and remains a major global health problem. In 2013, 9 million new cases were diagnosed and 1.5 million people died worldwide from tuberculosis. This dissertation aims at developing a new, ultrafine particle-based efficient antibiotic delivery system for the treatment of tuberculosis. The carrier material to make the rifampicin (RIF)-loaded particles is a low molecular weight star-shaped polymer produced from glucosamine (molecular core building unit) and L-lactide (GluN-LLA). Stable particles with a very high 50% drug loading capacity were made via electrohydrodynamic atomization. Prolonged …
Production Of Recombinant Human Coagulation Factor Ix By Transgenic Pig, Weijie Xu
Production Of Recombinant Human Coagulation Factor Ix By Transgenic Pig, Weijie Xu
Department of Chemical and Biomolecular Engineering: Theses and Student Research
Hemophilia B is the congenital bleeding disorder caused by deficiency in functional coagulation factor IX (FIX) and about 28,000 patients worldwide in 2012. And current treatment is restricted to protein-replacement therapy, which required FIX concentrates for patients’ life-time. Approximately 1 billion units FIX were consumed in 2012. However, still about 70-80% patients, mostly in developing countries, received inadequate or no treatment because of the unavailable and/or unaffordable FIX concentrates. Considering safety reasons, e.g. transmission of blood-borne diseases, the recombinant human FIX (rFIX) is recommended other than the plasma-derived FIX. However, only one rFIX is currently available on the market. The …